Antibody-targeted liposomes in cancer therapy and imaging

Bibliography

• Huang A, Kennel SJ, Huang L. Immunoliposome labeling: a sensitive and specific method for cell surface labeling. J Immunol Methods 1981;46(2):141-51
   PubMed Web of Science ®Google Scholar
• Huang A, Huang L, Kennel SJ. Monoclonal-antibody covalently coupled with fatty-acid – a reagent for in vitro liposome targeting. J Biol Chem 1980;255(17):8015-8
   PubMed Web of Science ®Google Scholar
• Hansen CB, Kao GY, Moase EH, Zalipsky S, Allen TM. Attachment of antibodies to sterically stabilized liposomes – evaluation, comparison and optimization of coupling procedures. Biochim Biophys Acta 1995;1239(2):133-44
   PubMed Web of Science ®Google Scholar
• Huang A, Kennel SJ, Huang L. Interactions of immunoliposomes with target-cells. J Biol Chem 1983;258(22):4034-40
   Web of Science ®Google Scholar
• Ishida T, Harashima H, Kiwada H. Interactions of liposomes with cells in vitro and in vivo: opsonins and receptors. Curr Drug Metab 2001;2(4):397-409
   PubMed Web of Science ®Google Scholar
• Gregoriadis G, Neerunjun ED. Homing of liposomes to target-cells. Biochem Biophys Res Commun 1975;65(2):537-44
   PubMed Web of Science ®Google Scholar
• Leserman LD, Weinstein JN, Blumenthal R, Sharrow SO, Terry WD. Binding of antigen-bearing fluorescent liposomes to the murine myeloma tumor Mopc 315. J Immunol 1979;122(2):585-91
   PubMed Web of Science ®Google Scholar
• Maruyama K. PEG-immunoliposome. Biosci Rep 2002;22(2):251-66
   PubMed Web of Science ®Google Scholar
• Huang A, Tsao YS, Kennel SJ, Huang L. Characterization of antibody covalently coupled to liposomes. Biochim Biophys Acta 1982;716(2):140-50
   PubMed Web of Science ®Google Scholar
• Huwyler J, Cerletti A, Fricker G, Eberle AN, Drewe J. By-passing of P-glycoprotein using immunoliposomes. J Drug Target 2002;10(1):73-9
   PubMed Web of Science ®Google Scholar
• Machy P, Barbet J, Leserman LD. Differential endocytosis of lymphocyte-T and lymphocyte-B surface molecules evaluated with antibody-bearing fluorescent liposomes containing methotrexate. Proc Natl Acad Sci USA 1982;79(13):4148-52
   PubMed Web of Science ®Google Scholar
• Barbet J, Machy P, Leserman LD. Monoclonal-antibody covalently coupled to liposomes – specific targeting to cells. J Supramol Struct Cell Biochem 1981;16(3):243-58
   PubMedGoogle Scholar
• Leserman LD, Machy P, Barbet J. Cell-specific drug transfer from liposomes bearing monoclonal-antibodies. Nature 1981;293(5829):226-8
   PubMed Web of Science ®Google Scholar
• Leserman LD, Barbet J, Kourilsky F, Weinstein JN. Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein-A. Nature 1980;288(5791):602-4
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Liposomes as targetable drug carriers. Crit Rev Ther Drug Carrier Syst 1985;2(1):65-115
   PubMedGoogle Scholar
• Peeters PAM, Storm G, Crommelin DJA. Immunoliposomes in vivo: state of the art. Adv Drug Deliv Rev 1987;1(3):249-66
   Google Scholar
• Wright S, Huang L. Antibody-directed liposomes as drug-delivery vehicles. Adv Drug Deliv Rev 1989;3(3):343-89
   Google Scholar
• Torchilin VP, Klibanov AL, Huang L, O'Donnell S, Nossiff ND, Khaw BA. Targeted accumulation of polyethylene glycol-coated immunoliposomes in infarcted rabbit myocardium. FASEB J 1992;6(9):2716-9
   PubMed Web of Science ®Google Scholar
• Sapra P, Tyagi P, Allen TM. Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv 2005;2(4):369-81
   PubMedGoogle Scholar
• Kirpotin DB, Park JW, Hong K, et al. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 1997;36:66-75
   PubMed Web of Science ®Google Scholar
• Allen TM, Brandeis E, Hansen CB, Kao GY, Zalipsky S. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer-cells. Biochim Biophys Acta 1995;1237(2):99-108
   PubMed Web of Science ®Google Scholar
• Lasic DD. Liposomes from Physics to Applications. Amsterdam: Elsevier; 1993
   Google Scholar
• Structure and Dynamics of Membranes. Handbook of Biological Physics. Amsterdam: Elsevier; 1995
   Google Scholar
• Needham D, Dewhirst MW. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv Rev 2001;53(3):285-305
   PubMed Web of Science ®Google Scholar
• Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999;51(4):691-743
   PubMed Web of Science ®Google Scholar
• Hope MJ, Bally MB, Webb G, Cullis PR. Production of large unilamellar vesicles by a rapid extrusion procedure – characterization of size distribution, trapped volume and ability to maintain a membrane-potential. Biochim Biophys Acta 1985;812(1):55-65
   PubMed Web of Science ®Google Scholar
• Szoka F, Papahadjopoulos D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci USA 1978;75(9):4194-8
   PubMed Web of Science ®Google Scholar
• Torchilin VP, Weissig V. Liposomes: A Practical Approach. Oxford University Press; 2003
   Google Scholar
• Philippot JR, Schuber F. Liposomes as Tools in Basic Research and Industry. CRC Press; 1995. p. 277
   Google Scholar
• Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002;2(10):750-63
   PubMed Web of Science ®Google Scholar
• Allen TM, Sapra P, Moase E. Use of the post-insertion method for the formation of ligand-coupled liposomes. Cell Mol Biol Lett 2002;7(3):889-94
   PubMed Web of Science ®Google Scholar
• Stealth Liposomes. Boca Raton, FL: CRC Press; 1995
   Google Scholar
• Scherphof GL, Kamps JAAM. Receptor versus non-receptor mediated clearance of liposomes. Adv Drug Deliv Rev 1998;32(1-2):81-97
   PubMed Web of Science ®Google Scholar
• Moghimi SM. Mechanisms of splenic clearance of blood-cells and particles – towards development of new splenotropic agents. Adv Drug Deliv Rev 1995;17(1):103-15
   Web of Science ®Google Scholar
• Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001;53(2):283-318
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Porter CJH, Muir IS, Illum L, Davis SS. Non-phagocytic uptake of intravenously injected microspheres in rat spleen – influence of particle-size and hydrophilic coating. Biochem Biophys Res Commun 1991;177(2):861-6
   PubMed Web of Science ®Google Scholar
• Klibanov AL, Maruyama K, Beckerleg AM, Torchilin VP, Huang L. Activity of amphipathic poly(ethylene glycol)-5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. Biochim Biophys Acta 1991;1062(2):142-8
   PubMed Web of Science ®Google Scholar
• Liu F, Liu DX. Serum independent liposome uptake by mouse liver. Biochim Biophys Acta 1996;1278(1):5-11
   PubMed Web of Science ®Google Scholar
• Ishida T, Harashima H, Kiwada H. Liposome clearance. Biosci Rep 2002;22(2):197-224
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hamad I, Andresen TL, Jorgensen K, Szebeni J. Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. FASEB J 2006;20(14):2591-3
   PubMed Web of Science ®Google Scholar
• Zhang JS, Liu F, Huang L. Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity. Adv Drug Deliv Rev 2005;57(5):689-98
   PubMed Web of Science ®Google Scholar
• Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 1988;85(18):6949-53
   PubMed Web of Science ®Google Scholar
• Allen C, Dos Santos N, Gallagher R, et al. Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Biosci Rep 2002;22(2):225-50
   PubMed Web of Science ®Google Scholar
• Yan XD, Scherphof GL, Kamps JA. Liposome opsonization. J Liposome Res 2005;15(1-2):109-39
   PubMed Web of Science ®Google Scholar
• Degennes PG. Conformations of polymers attached to an interface. Macromolecules 1980;13(5):1069-75
   Web of Science ®Google Scholar
• Efremova NV, Bondurant B, O'Brien DF, Leckband DE. Measurements of interbilayer forces and protein adsorption on uncharged lipid bilayers displaying poly(ethylene glycol) chains. Biochemistry 2000;39(12):3441-51
   PubMed Web of Science ®Google Scholar
• Price ME, Cornelius RM, Brash JL. Protein adsorption to polyethylene glycol modified liposomes from fibrinogen solution and from plasma. Biochim Biophys Acta 2001;1512(2):191-205
   PubMed Web of Science ®Google Scholar
• Dos Santos N, Allen C, Doppen AM, et al. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta 2007;1768(6):1367-77
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Szebeni J, Savay S, et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol 2003;14(9):1430-7
   PubMed Web of Science ®Google Scholar
• Szebeni J, Baranyi L, Savay S, et al. Role of complement activation in hypersensitivity reactions to doxil and HYNICPEG liposomes: experimental and clinical studies. J Liposome Res 2002;12(1-2):165-72
   PubMed Web of Science ®Google Scholar
• Xiao Z, McQuarrie SA, Suresh MR, Mercer JR, Gupta S, Miller GG. A three-step strategy for targeting drug carriers to human ovarian carcinoma cells in vitro. J Biotechnol 2002;94(2):171-84
   PubMed Web of Science ®Google Scholar
• Ishida T, Iden DL, Allen TM. A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs. FEBS Lett 1999;460(1):129-33
   PubMed Web of Science ®Google Scholar
• Iden DL, Allen TM. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochim Biophys Acta 2001;1513(2):207-16
   PubMed Web of Science ®Google Scholar
• Mamot C, Drummond DC, Noble CO, et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res 2005;65(24):11631-8
   PubMed Web of Science ®Google Scholar
• Kirpotin DB, Drummond DC, Shao Y, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006;66(13):6732-40
   PubMed Web of Science ®Google Scholar
• Sofou S, Kappel BJ, Jaggi J, McDevitt MR, Scheinberg DA, Sgouros G. Enhanced retention of the alpha-particle emitting daughters of actinium-225 by liposome carriers. Bioconjug Chem 2007;18(6):2061-7
   PubMed Web of Science ®Google Scholar
• Emfietzoglou D, Kostarelos K, Sgouros G. An analytic dosimetry study for the use of radionuclide-liposome conjugates in internal radiotherapy. J Nucl Med 2001;42(3):499-504
   PubMed Web of Science ®Google Scholar
• Syrigos KN, Vile RG, Peters AM, Harrington KJ. Biodistribution and pharmacokinetics of 111In-DTPA-labelled pegylated liposomes after intraperitoneal injection. Acta Oncol 2003;42(2):147-53
   PubMed Web of Science ®Google Scholar
• Drummond DC, Marx C, Guo ZX, et al. Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in lipsomes or ErbB2-targeted immunoliposomes. Clin Cancer Res 2005;11(9):3392-401
   PubMed Web of Science ®Google Scholar
• Nellis DF, Ekstrom DL, Kirpotin DB, et al. Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification. Biotechnol Prog 2005;21(1):205-20
   PubMed Web of Science ®Google Scholar
• Nellis DF, Giardina SL, Janini GM, et al. Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-Lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis. Biotechnol Prog 2005;21(1):221-32
   PubMed Web of Science ®Google Scholar
• Ceh B, Lasic DD. A rigorous theory of remote loading of drugs into liposomes. Langmuir 1995;11(9):3356-68
   Web of Science ®Google Scholar
• Haran G, Cohen R, Bar LK, Barenholz Y. Transmembrane ammonium-sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1993;1151(2):201-15
   PubMed Web of Science ®Google Scholar
• Drummond DC, Noble CO, Guo ZX, Hong K, Park JW, Kirpotin DB. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res 2006;66(6):3271-7
   PubMed Web of Science ®Google Scholar
• Noble CO, Krauze MT, Drummond DC, et al. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res 2006;66(5):2801-6
   PubMed Web of Science ®Google Scholar
• Park JW, Hong K, Kirpotin DB, Papahadjopoulos D, Benz CC. Immunoliposomes for cancer treatment. Adv Pharmacol 1997;40:399-435
   PubMedGoogle Scholar
• Maruyama K, Takahashi N, Tagawa T, Nagaike K, Iwatsuru M. Immunoliposomes bearing polyethyleneglycol-coupled Fab' fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo. FEBS Lett 1997;413(1):177-80
   PubMed Web of Science ®Google Scholar
• Hosokawa S, Tagawa T, Niki H, Hirakawa Y, Nohga K, Nagaike K. Efficacy of immunoliposomes on cancer models in a cell-surface-antigen-density-dependent manner. Br J Cancer 2003;89(8):1545-51
   PubMed Web of Science ®Google Scholar
• Sapra P, Allen TM. Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes (vol 10, pg 2530, 2004). Clin Cancer Res 2004;10(14):4893
   Web of Science ®Google Scholar
• Allen TM, Mumbengegwi DR, Charrois GJR. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Clin Cancer Res 2005;11(9):3567-73
   PubMed Web of Science ®Google Scholar
• Nichols JW, Deamer DW. Catecholamine uptake and concentration by liposomes maintaining pH-gradients. Biochim Biophys Acta 1976;455(1):269-71
   PubMed Web of Science ®Google Scholar
• Mayer LD, Bally MB, Hope MJ, Cullis PR. Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane-potential. Biochim Biophys Acta 1985;816(2):294-302
   PubMed Web of Science ®Google Scholar
• Suzuki S, Watanabe S, Masuko T, Hashimoto Y. Preparation of long-circulating immunoliposomes containing adriamycin by a novel method to coat immunoliposomes with poly(ethylene glycol). Biochim Biophys Acta 1995;1245(1):9-16
   PubMed Web of Science ®Google Scholar
• Bennett JA, Pilon VA, Macdowell RT. Evaluation of growth and histology of human-tumor xenografts implanted under the renal capsule of immunocompetent and immunodeficient mice. Cancer Res 1985;45(10):4963-9
   PubMed Web of Science ®Google Scholar
• Moreira JN, Ishida T, Gaspar R, Allen TM. Use of the post-insertion technique to insert peptide ligands into pre-formed stealth liposomes with retention of binding activity and cytotoxicity. Pharm Res 2002;19(3):265-9
   PubMed Web of Science ®Google Scholar
• Lukyanov AN, Elbayoumi TA, Chakilam AR, Torchilin VP. Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J Control Rel 2004;100(1):135-44
   PubMed Web of Science ®Google Scholar
• Klibanov AL, Muzykantov VR, Ivanov NN, Torchilin VP. Evaluation of quantitative parameters of the interaction of antibody-bearing liposomes with target antigens. Anal Biochem 1985;150(2):251-7
   PubMed Web of Science ®Google Scholar
• Mastrobattista E, Koning GA, Storm G. Immunoliposomes for the targeted delivery of antitumor drugs. Adv Drug Deliv Rev 1999;40(1-2):103-27
   PubMed Web of Science ®Google Scholar
• Spragg DD, Alford DR, Greferath R, et al. Immunotargeting of liposomes to activated vascular endothelial cells: a strategy for site-selective delivery in the cardiovascular system. Proc Natl Acad Sci USA 1997;94(16):8795-800
   PubMed Web of Science ®Google Scholar
• Shi NY, Pardridge WM. Noninvasive gene targeting to the brain. Proc Natl Acad Sci USA 2000;97(13):7567-72
   PubMed Web of Science ®Google Scholar
• Tan PH, Manunta M, Ardjomand N, et al. Antibody targeted gene transfer to endothelium. J Gene Med 2003;5(4):311-23
   PubMed Web of Science ®Google Scholar
• Xu L, Tang WH, Huang CC, et al. Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv. Mol Med 2001;7(10):723-34
   PubMed Web of Science ®Google Scholar
• Yu W, Pirollo KF, Rait A, et al. A sterically stabilized immunolipoplex for systemic administration of a therapeutic gene. Gene Ther 2004;11(19):1434-40
   PubMed Web of Science ®Google Scholar
• Yu W, Pirollo KF, Yu B, et al. Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide. Nucleic Acids Res 2004;32(5)
   Google Scholar
• Rait AS, Pirollo KF, Ulick D, Cullen K, Chang EH. HER-2-targeted antisense oligonucleotide results in sensitization of head and neck cancer cells to chemotherapeutic agents. Ther Oligonucleotides 2003;1002:78-89
   Web of Science ®Google Scholar
• Jhaveri MS, Rait AS, Chung KN, Trepel JB, Chang EH. Antisense oligonucleotides targeted to the human alpha folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment. Mol Cancer Ther 2004;3(12):1505-12
   PubMed Web of Science ®Google Scholar
• Pirollo KF, Zon G, Rait A, et al. Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. Hum Gene Ther 2006;17(1):117-24
   PubMed Web of Science ®Google Scholar
• Koning GA, Morselt HWM, Velinova MJ, et al. Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells. Biochim Biophys Acta 1999;1420(1-2):153-67
   PubMed Web of Science ®Google Scholar
• Rodrigues ML, Presta LG, Kotts CE, et al. Development of a humanized disulfide-stabilized anti-p185(HER2) Fv-?-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug. Cancer Res 1995;55(1):63-70
   PubMed Web of Science ®Google Scholar
• Dubowchik GM, Walker MA. Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharmacol Ther 1999;83(2):67-123
   PubMed Web of Science ®Google Scholar
• Harding JA, Engbers CM, Newman MS, Goldstein NI, Zalipsky S. Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes. Biochim Biophys Acta 1997;1327(2):181-92
   PubMed Web of Science ®Google Scholar
• Phillips WT, Goins B. Targeted delivery of imaging agents by liposomes. In: Torchilin VP, editor. Handbook of Targeted Delivery of Imaging Agents. Boca Rota, FL: CRC Press, Inc.; 1995. p. 149-73
   Google Scholar
• Elbayoumi TA, Torchilin VP. Tumor-targeted immuno-liposomes for delivery of therapeutics and diagnostics. Pharm Eng 2006;26(5):96-104
   Google Scholar
• Erdogan S, Roby A, Torchilin VP. Enhanced tumor visualization by ?-scintigraphy with 111In-labeled polychelating-polymer-containing immunoliposomes. Mol Pharm 2006;3(5):525-30
   PubMed Web of Science ®Google Scholar
• Kostarelos K, Emfietzoglou D, Papakostas A, Yang WH, Ballangrud A, Sgouros G. Binding and interstitial penetration of liposomes within avascular tumor spheroids. Int J Cancer 2004;112(4):713-21
   PubMed Web of Science ®Google Scholar
• Kostarelos K, Emfietzoglou D, Papakostas A, Yang WH, Ballangrud A, Sgouros G. Engineering lipid vesicles of enhanced intratumoral transport capabilities: correlating liposome characteristics with penetration into human prostate tumor spheroids. J Liposome Res 2005;15(1-2):15-27
   PubMed Web of Science ®Google Scholar
• Emfietzoglou D, Kostarelos K, Papakostas A, et al. Liposome-mediated radiotherapeutics within avascular tumor spheroids: comparative dosimetry study for various radionuclides, liposome systems, and a targeting antibody. J Nucl Med 2005;46(1):89-97
   PubMed Web of Science ®Google Scholar
• Kostarelos K, Emfietzoglou D. Liposomes as carriers of radionuclides: from imaging to therapy. J Liposome Res 1999;9(4):429-60
   Web of Science ®Google Scholar
• Kostarelos K, Emfietzoglou D. Tissue dosimetry of liposome–radionuclide complexes for internal radiotherapy: toward liposome-targeted therapeutic radiopharmaceuticals. Anticancer Res 2000;20(5):3339-45
   PubMed Web of Science ®Google Scholar
• Bao A, Goins B, Klipper R, Negrete G, Phillips WT. 186Re-liposome labeling using 186Re–SNS/S complexes: in vitro stability, imaging, and biodistribution in rats. J Nucl Med 2003;44(12):1992-9
   PubMed Web of Science ®Google Scholar
• Kabalka G, Buonocore E, Hubner K. Gadolinium-labeled liposomes: targeted MR contrast agents for the liver and spleen. Radiology 1987;163(1):255-8
   PubMed Web of Science ®Google Scholar
• Kabalka GW, Davis MA, Moss TH, et al. Gadolinium-labeled liposomes containing various amphiphilic Gd-DTPA derivatives: targeted MRI contrast enhancement agents for the liver. Magn Reson Med 1991;19(2):406-15
   PubMed Web of Science ®Google Scholar
• Erdogan S, Roby A, Sawant R, Hurley J, Torchilin VP. Gadolinium-loaded polychelating polymer-containing cancer cell-specific immunoliposomes. J Liposome Res 2006;16(1):45-55
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Polymeric contrast agents for medical imaging. Curr Pharm Biotechnol 2000;1(2):183-215
   PubMedGoogle Scholar
• Iakoubov LZ, Torchilin VP. Nucleosome-releasing treatment makes surviving tumor cells better targets for nucleosome-specific anticancer antibodies. Cancer Detect Prev 1998;22(5):470-5
   PubMedGoogle Scholar
• Iakoubov LZ, Torchilin VP. A novel class of antitumor antibodies: nucleosome-restricted antinuclear autoantibodies (ANA) from healthy aged nonautoimmune mice. Oncol Res 1997;9(8):439-46
   PubMed Web of Science ®Google Scholar
• Jonasdottir TJ, Fisher DR, Borrebaek J, Bruland OS, Larsen RH. First in vivo evaluation of liposome-encapsulated 223Ra as a potential alpha-particle-emitting cancer therapeutic agent. Anticancer Res 2006;26(4B):2841-8
   PubMed Web of Science ®Google Scholar
• Sofou S, Thomas JL, Lin HY, McDevitt MR, Scheinberg DA, Sgouros G. Engineered liposomes for potential {alpha}-particle therapy of metastatic cancer. J Nucl Med 2004;45(2):253-60
   PubMed Web of Science ®Google Scholar
• Henriksen G, Schoultz BW, Hoff P, Larsen RH. Potential in vivo generator for alpha-particle therapy with Bi-212: presentation of a system to minimize escape of daughter nuclide after decay of Pb-212 to Bi-212. Radiochimica Acta 2003;91(2):109-13
   Web of Science ®Google Scholar
• Papahadjopoulos D, Allen TM, Gabizon A, et al. Sterically stabilized liposomes – improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 1991;88(24):11460-4
   PubMed Web of Science ®Google Scholar
• Folkman J, Klagsbrun M. Angiogenic factors. Science 1987;235(4787):442-7
   PubMed Web of Science ®Google Scholar
• Matter A. Tumor angiogenesis as a therapeutic target. Drug Discov Today 2001;6(19):1005-24
   PubMed Web of Science ®Google Scholar
• Pastorino F, Brignole C, Di Paolo D, et al. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res 2006;66(20):10073-82
   PubMed Web of Science ®Google Scholar
• Fujimori K, Covell DG, Fletcher JE, Weinstein JN. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 1990;31(7):1191-8
   PubMed Web of Science ®Google Scholar
• Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 1988;48(24 Pt 1):7022-32
   PubMed Web of Science ®Google Scholar
• Kostarelos K, Emfietzoglou D, Papakostas A, Yang WH, Ballangrud A, Sgouros G. Binding and interstitial penetration of liposomes within avascular tumor spheroids. Int J Cancer 2004;112(4):713
   PubMed Web of Science ®Google Scholar
• Davies CDL, Lundstrom LM, Frengen J, et al. Radiation improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts. Cancer Res 2004;64(2):547-53
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Gotoh M, Muro K, et al. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol 2004;15(3):517-25
   PubMed Web of Science ®Google Scholar
• Friend DS, Papahadjopoulos D, Debs RJ. Endocytosis and intracellular processing accompanying transfection mediated by cationic liposomes. Biochim Biophys Acta 1996;1278(1):41-50
   PubMed Web of Science ®Google Scholar
• Noguchi A, Furuno T, Kawaura C, Nakanishi M. Membrane fusion plays an important role in gene transfection mediated by cationic liposomes. FEBS Lett 1998;433(1-2):169-73
   PubMed Web of Science ®Google Scholar
• Stebelska K, Wyrozumska P, Gubernator J, Sikorski AF. Highly fusogenic cationic liposomes transiently permeabilize the plasma membrane of HeLa cells. Cell Mol Biol Lett 2007;12(1):39-50
   PubMed Web of Science ®Google Scholar